These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17705287)

  • 1. Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME).
    Dai WG; Dong LC; Shi X; Nguyen J; Evans J; Xu Y; Creasey AA
    J Pharm Sci; 2007 Nov; 96(11):2957-69. PubMed ID: 17705287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simplified method to screen for in-vivo performance of oral lipid formulations.
    Kilic M; Dressman J
    J Pharm Pharmacol; 2014 May; 66(5):615-23. PubMed ID: 24313318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation.
    Berben P; Ashworth L; Beato S; Bevernage J; Bruel JL; Butler J; Dressman J; Schäfer K; Hutchins P; Klumpp L; Mann J; Nicolai J; Ojala K; Patel S; Powell S; Rosenblatt K; Tomaszewska I; Williams J; Augustijns P
    Eur J Pharm Biopharm; 2019 Jul; 140():141-148. PubMed ID: 31051249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
    Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
    Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs.
    Schwebel HJ; van Hoogevest P; Leigh ML; Kuentz M
    Pharm Dev Technol; 2011 Jun; 16(3):278-86. PubMed ID: 20214530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
    Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.
    Madsen CM; Boyd B; Rades T; Müllertz A
    Eur J Pharm Sci; 2016 Aug; 91():31-9. PubMed ID: 27260089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids.
    Clarysse S; Brouwers J; Tack J; Annaert P; Augustijns P
    Eur J Pharm Sci; 2011 Jul; 43(4):260-9. PubMed ID: 21570465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F; Holm P; Larsen F; Steffansen B
    Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability.
    Dahlgren D; Venczel M; Ridoux JP; Skjöld C; Müllertz A; Holm R; Augustijns P; Hellström PM; Lennernäs H
    Eur J Pharm Biopharm; 2021 Jun; 163():240-251. PubMed ID: 33872761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state.
    Arndt M; Chokshi H; Tang K; Parrott NJ; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2013 Aug; 84(3):633-41. PubMed ID: 23434923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.
    Fagerberg JH; Tsinman O; Sun N; Tsinman K; Avdeef A; Bergström CA
    Mol Pharm; 2010 Oct; 7(5):1419-30. PubMed ID: 20507160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions.
    de Campos DR; Vieira NR; Bernasconi G; Barros FA; Meurer EC; Marchioretto MA; Coelho EC; Calafatti SA; Sommer C; Couto JM; Buranello S; Silva AR; Amarante AR; Abib E; Júnior JP
    Arzneimittelforschung; 2007; 57(6):309-14. PubMed ID: 17688075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug precipitation inhibitors in supersaturable formulations.
    Xu S; Dai WG
    Int J Pharm; 2013 Aug; 453(1):36-43. PubMed ID: 23680727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.